Blocking Cationic Antimicrobial Peptide-Resistance in Pseudomonas aeruginosa
阻断铜绿假单胞菌的阳离子抗菌肽耐药性
基本信息
- 批准号:10378040
- 负责人:
- 金额:$ 10.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdjuvantAdjuvant StudyAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsAntimicrobial Cationic PeptidesArabinoseAreaBacteriaBacterial Drug ResistanceBacterial InfectionsBindingBiological AssayCOVID-19COVID-19 pandemicCalorimetryCarboxy-LyasesChargeClinicColistinCombined Modality TherapyComplementDevelopmentDisease OutbreaksDoseDrug resistanceEffectivenessElectrostaticsEnsureEnzymesFoundationsFundingFutureGoalsGram-Negative BacteriaHospitalsInfectionKineticsLegal patentLifeLipid ALipidsLongitudinal StudiesMass Spectrum AnalysisMediatingMembraneMicrobial BiofilmsModificationMolecular Mechanisms of ActionMolecular TargetMotivationMulti-Drug ResistanceNosocomial InfectionsPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePredispositionPrivatizationPseudomonas aeruginosaPublic HealthResearchResistanceResistance developmentResortSARS coronavirusSalmonellaSamplingSavingsScienceSerial PassageSevere Acute Respiratory SyndromeSignal PathwaySourceTestingTherapeuticTherapeutic IndexTimeTitrationsUnderrepresented PopulationsUnderrepresented StudentsUnited States National Institutes of HealthWorkanalogbactericidebasecarbapenem-resistant Enterobacteriaceaecareercolistin resistanceeffective therapyexperimental studyinhibitormultidrug-resistant Pseudomonas aeruginosamutantpandemic diseasepathogenpost SARS-CoV-2 infectionpreventresistant strainsecondary infectionside effectsmall molecule inhibitortreatment strategy
项目摘要
Project Summary/Abstract
Infections with antibiotic-resistant strains of bacteria are a looming public health threat to the nation. The
problem is especially pressing in the era of COVID-19, where secondary infections were identified in half of
hospitalized patients who did not survive. More research on the identity of the secondary infections in the
current outbreak still needs to be conducted, but in the SARS coronavirus outbreak, gram-negative bacteria
were the most common source of the hospital-acquired infections. Gram-negative bacteria like Pseudomonas
aeruginosa have few effective treatments, making any resistant strains particularly difficult to treat. Cationic
antimicrobial peptides (CAPs) like colistin are currently used as last line therapies to treat infections with
multidrug-resistant strains, however, colistin-resistant strains are increasingly encountered. P. aeruginosa
becomes resistant to CAPs by modifying the lipids of its outer membrane to reduce the net negative charge.
Without the favorable electrostatic interaction between the positively-charged CAP and the negatively-
charged bacterial outer membrane, the antibiotic cannot enter and kill the bacterium. Our goal is to develop
and characterize inhibitors of the CAP-resistance pathway in the bacterium. If the outer membrane remains
negatively charged, the CAP should continue to work. The inhibitors could be used as an adjuvant in a
combination therapy along with a CAP to treat resistant infections.
In the first funding period, we identified a suite of compounds that act as antibiotic adjuvants, potentiating
susceptibility to colistin. In the current work, we propose to characterize the efficacy of the combination
treatment (Aim 1). We will investigate activity toward biofilms, resistant strains, and under resistance-
inducing conditions. The kinetics of killing and the development of resistance will also be studied. Our current
hypothesis is that the antibiotic adjuvant acts by inhibition of ArnA, a key bifunctional biosynthetic enzyme of
the lipid modification pathway. We will study the adjuvant’s effects on the ArnA-mediated resistance
pathway through analysis of the lipids by mass spectrometry and direct interactions with ArnA in kinetics and
binding experiments (Aim 2). The proposed work will validate the further development of the combination
therapy towards use in the clinic. Confirmation of the molecular target will also guide the optimization of even
more potent inhibitors in future work. Deciphering the molecular target could also allow us to extend the
therapy to other gram-negative bacteria like carbapenem-resistant Enterobacteriaceae and drug-resistant
Salmonella as a long-term goal. The first-in-class inhibitor has the potential to widen the therapeutic index of
colistin, minimizing the drug’s serious side effects, as well as to enable the treatment of colistin-resistant
strains, ensuring the continued efficacy of the life-saving drug.
项目总结/摘要
抗药性细菌菌株的感染对国家的公共卫生构成了迫在眉睫的威胁。的
在COVID-19时代,问题尤其紧迫,一半的人发现了二次感染
没有存活下来的住院患者。对继发性感染的身份进行更多的研究,
目前的疫情仍需进行,但在SARS冠状病毒疫情中,革兰氏阴性菌
是医院感染的最常见来源。革兰氏阴性菌,如假单胞菌
铜绿假单胞菌几乎没有有效的治疗方法,使得任何耐药菌株特别难以治疗。
抗微生物肽(CAP)如粘菌素目前用作治疗感染的最后一线疗法,
多药耐药菌株,然而,越来越多地遇到粘菌素耐药菌株。铜绿假单胞菌
通过修饰其外膜的脂质以减少净负电荷而变得对CAP具有抗性。
在带正电的CAP和带负电的CAP之间没有有利的静电相互作用的情况下,
当细菌外膜带电时,抗生素不能进入并杀死细菌。我们的目标是开发
并表征细菌中CAP抗性途径的抑制剂。如果外膜仍然存在
负电荷,联合呼吁程序应继续工作。所述抑制剂可用作免疫抑制剂中的佐剂。
联合治疗沿着CAP以治疗耐药感染。
在第一个资助期内,我们确定了一套作为抗生素佐剂的化合物,
对粘菌素敏感。在目前的工作中,我们建议对联合用药的疗效进行表征
治疗(目标1)。我们将研究对生物膜、耐药菌株和耐药菌株的活性-
诱导条件。还将研究杀灭的动力学和抗性的发展。我们目前
假设是抗生素佐剂通过抑制ArnA起作用,ArnA是一种关键的双功能生物合成酶,
脂质修饰途径。我们将研究佐剂对ArnA介导的抗性的影响
通过质谱法分析脂质和在动力学中与ArnA的直接相互作用,
结合实验(目标2)。所提出的工作将验证该组合的进一步发展
在临床上的应用。分子靶点的确认也将指导甚至是
更有效的抑制剂在未来的工作。破译分子靶点也可以让我们扩展
治疗其他革兰氏阴性菌,如碳青霉烯耐药肠杆菌科和耐药
沙门氏菌作为一个长期目标。这种一流的抑制剂有可能扩大
粘菌素,最大限度地减少药物的严重副作用,以及使粘菌素耐药的治疗
菌株,确保救生药物的持续有效性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laura C. Miller Conrad其他文献
Laura C. Miller Conrad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laura C. Miller Conrad', 18)}}的其他基金
Blocking cationic antimicrobial peptide-resistance in Pseudomonas aeruginosa
阻断铜绿假单胞菌的阳离子抗菌肽耐药性
- 批准号:
9247785 - 财政年份:2016
- 资助金额:
$ 10.42万 - 项目类别:
Blocking Cationic Antimicrobial Peptide-Resistance in Pseudomonas aeruginosa
阻断铜绿假单胞菌的阳离子抗菌肽耐药性
- 批准号:
10172279 - 财政年份:2016
- 资助金额:
$ 10.42万 - 项目类别:
Blocking cationic antimicrobial peptide-resistance in Pseudomonas aeruginosa
阻断铜绿假单胞菌的阳离子抗菌肽耐药性
- 批准号:
9072275 - 财政年份:2016
- 资助金额:
$ 10.42万 - 项目类别:
Blocking Cationic Antimicrobial Peptide-Resistance in Pseudomonas aeruginosa
阻断铜绿假单胞菌的阳离子抗菌肽耐药性
- 批准号:
10598516 - 财政年份:2016
- 资助金额:
$ 10.42万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 10.42万 - 项目类别: